Jim Simons’s Foghorn Therapeutics FHTX Stock Holding History

Jim Simons’s Portfolio FHTX Stock Details FHTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.94M	Buy	406,425 +108,689	+37%	+$597K	﹤0.01%	1913
2025 Q4	$1.61M	Buy	297,736 +179,500	+152%	+$814K	﹤0.01%	2004
2025 Q3	$578K	Buy	118,236 +55,600	+89%	+$295K	﹤0.01%	2728
2025 Q2	$294K	Buy	62,636 +5,400	+9%	+$22.6K	﹤0.01%	3044
2025 Q1	$209K	Buy	57,236 +9,500	+20%	+$43.3K	﹤0.01%	3062
2024 Q4	$225K	Buy	47,736 +22,500	+89%	+$164K	﹤0.01%	3132
2024 Q3	$235K	Buy	25,236 +14,536	+136%	+$105K	﹤0.01%	3073
2024 Q2	$61.5K	Buy	+10,700	New	+$63.7K	﹤0.01%	3259

Other funds holding FHTX

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Jim Simons's FHTX Position: Q1 2026 in Review

Jim Simons increased its Foghorn Therapeutics (FHTX) stake by 37% in Q1 2026, buying an estimated $597K and bringing the position to 406,425 shares worth $1.94M. The position accounts for ﹤0.01% of the portfolio, ranked #1913.

Jim Simons first reported a position in FHTX in Q2 2024 and has held it in 8 quarters since. 105 funds tracked by Wall St. Rank hold FHTX as of Q1 2026.

Jim Simons held 406,425 shares of Foghorn Therapeutics worth $1.94M as of Q1 2026.
Jim Simons bought 108,689 Foghorn Therapeutics shares in Q1 2026, an estimated $597K.
Foghorn Therapeutics made up ﹤0.01% of Jim Simons's portfolio in Q1 2026, its #1913 holding.
Jim Simons first reported a position in Foghorn Therapeutics in Q2 2024 and has held it in 8 quarters since.
105 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.